Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus

Phase 3

• Conditions: non specified coronavirus infection/ coronavirus; B34.2

• Registration Number: RBR-9d8z6m
• Lead Sponsor: Hospital do Coração

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-03-27
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients admitted to the ICU or Hospital with suspected or confirmed COVID-19

Exclusion Criteria

Presence of any of the following: Need to supplement oxygen more than 4L; Use of high flow nasal catheter; Use of non-invasive ventilation; Use of mechanical ventilation; Use of hidroxichoroquine, chloroquine,
azithromycin or other macrolide over 24 hours; History of severe ventricular or QTC equal or grater than 48 ms cardiac arrithmia; History of hepatic desease (cirrosis); Renal dysfunction (estimated glomerular filtration rate [eGFR] less than 30ml/min/1.73m2, using MDRD or CKD-EPI method); Patients with retinopathy or macular degeneration; Children under 18 years;Pregnancy; Allergy to chloroquine and derivatives; Allergy to azythromicyn; Patients in hospital over 48hr; Patients with symptoms over 14 days

Study & Design

• Study Type: Intervention
• Study Design: Not specified